Alecta Tjanstepension Omsesidigt Acquires 184,900 Shares of AbbVie Inc. $ABBV

Key Points

• Alecta Tjanstepension Omsesidigt increased its stake in AbbVie by 16.0%, buying 184,900 shares to hold 1,343,800 shares (about 0.08% of AbbVie) valued at $307,005,000, making AbbVie its 21st-largest holding (≈1.3% of Alecta's portfolio).
• AbbVie beat quarterly estimates with $2.65 EPS (vs. $2.59 expected) and $15.0B revenue (up 12.4% YoY), declared a $1.73 quarterly dividend (3.4% yield), and carries a consensus "Moderate Buy" analyst rating with an average price target of $252.90.
• Risks include the U.S. FDA declining approval of AbbVie's wrinkle treatment over manufacturing concerns, notable insider sales (SVP David Ryan Purdue sold 5,230 shares; EVP Perry C. Siatis sold 22,381 shares), while institutional investors still own about 70.23% of the company.

Alecta Tjanstepension Omsesidigt raised its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 16.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,343,800 shares of the company's stock after buying an additional 184,900 shares during the quarter. AbbVie accounts for approximately 1.3% of Alecta Tjanstepension Omsesidigt's holdings, making the stock its 21st biggest holding. Alecta Tjanstepension Omsesidigt owned approximately 0.08% of AbbVie worth $307,005,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in AbbVie by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company's stock worth $41,155,601,000 after acquiring an additional 448,554 shares during the last quarter. Public Sector Pension Investment Board grew its holdings in AbbVie by 17.0% during the 3rd quarter. Public Sector Pension Investment Board now owns 1,044,690 shares of the company's stock worth $241,888,000 after acquiring an additional 151,644 shares during the last quarter. Thornburg Investment Management Inc. grew its holdings in AbbVie by 25.5% during the 3rd quarter. Thornburg Investment Management Inc. now owns 401,760 shares of the company's stock worth $93,024,000 after acquiring an additional 81,625 shares during the last quarter. Channing Capital Management LLC grew its holdings in AbbVie by 10.5% during the 3rd quarter. Channing Capital Management LLC now owns 55,647 shares of the company's stock worth $12,885,000 after acquiring an additional 5,302 shares during the last quarter. Finally, Procyon Advisors LLC grew its holdings in AbbVie by 19.9% during the 4th quarter. Procyon Advisors LLC now owns 32,752 shares of the company's stock worth $7,484,000 after acquiring an additional 5,427 shares during the last quarter. Institutional investors own 70.23% of the company's stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New long‑term gastroenterology data — AbbVie presented 18 abstracts at Digestive Disease Week showing supportive long‑term and real‑world data for SKYRIZI (risankizumab) and RINVOQ (upadacitinib), which can bolster label positioning and commercial durability in IBD. AbbVie Highlights New Long-Term Data at DDW (PR Newswire)
• Positive Sentiment: Dividend appeal — several income-oriented outlets featured AbbVie as a high‑yield, reliable dividend stock (Dividend King), which supports steady investor demand from income-focused funds. 6 Pharma Dividend Stocks Yielding Up to 6.44% (247WallSt)
• Positive Sentiment: Investor visibility — management will appear at the Bank of America Securities Healthcare Conference on May 13 (fireside chat), offering a chance for updated commercial color or guidance that could move the stock. AbbVie to Present at the Bank of America Securities Healthcare Conference (PR Newswire)
• Neutral Sentiment: Analyst/retail interest — multiple trending and “is it a buy?” pieces are driving attention but offer mixed views; useful for gauging retail flow rather than immediate fundamental change. Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? (Zacks)
• Neutral Sentiment: Strategic/tech engagement — AbbVie appeared among industry leaders at Zifo’s SiEE summit on practical AI in life sciences; longer‑term operational upside but unclear near‑term impact. Zifo's SiEE Boston Summit Charts New Roadmap (Yahoo)
• Neutral Sentiment: Peripheral industry moves — news such as Timothy P. Walbert joining Patient Square is industry‑level and not directly tied to AbbVie fundamentals. Timothy P. Walbert Joins Patient Square Capital (Yahoo)
• Negative Sentiment: Regulatory/manufacturing setback — the U.S. FDA declined to approve AbbVie’s wrinkle treatment over manufacturing concerns (reported April 23), highlighting execution and regulatory risk that can weigh on aesthetics revenue and investor confidence. FDA Declines Approval of AbbVie Wrinkle Treatment (MSN)

Insider Buying and Selling

In related news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company's stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.06% of the company's stock.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $205.14 on Thursday. The company has a market capitalization of $362.72 billion, a price-to-earnings ratio of 101.05, a P/E/G ratio of 0.71 and a beta of 0.32. The firm's 50 day simple moving average is $213.69 and its 200 day simple moving average is $221.19. AbbVie Inc. has a fifty-two week low of $176.57 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 911.57%. AbbVie's revenue for the quarter was up 12.4% on a year-over-year basis. During the same period last year, the company posted $2.46 EPS. Equities research analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie's dividend payout ratio (DPR) is currently 340.89%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ABBV shares. Barclays started coverage on shares of AbbVie in a research report on Thursday, February 19th. They set an "overweight" rating and a $275.00 target price on the stock. The Goldman Sachs Group restated a "neutral" rating and set a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. UBS Group cut their target price on shares of AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a research report on Thursday, February 5th. William Blair restated an "outperform" rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Morgan Stanley upped their target price on shares of AbbVie from $270.00 to $278.00 and gave the company an "overweight" rating in a research report on Thursday, April 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of "Moderate Buy" and an average price target of $252.90.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.